Table 3.
Significantly regulated transcripts of metabolic pathways in liver tissue between two ontogenetic stages within one dietary group (Ingenuity Pathway Analysis)
| Ontogenetic comparison | Diet | Regulated pathway | Direction of regulation | P value | No. of regulated genes | Genes involved in pathway |
|---|---|---|---|---|---|---|
| 94 dpc vs. 1 dpn | AP | AMPK signaling | up | 6.96*E-3 | 8 | AKT2, INSR, PIK3C2A, PIK3R1, PPM1B, PRKAA1, PRKACB, RAC1 |
| AP | Mitotic roles of Polo- like kinase | down | 3.25*E-4 | 7 | CCNB1, CCNB2, CDC25B, CHEK2, KIF11, PLK4, PTTG1 | |
| AP | Pyrimidine metabolism | down | 2.52*E-3 | 10 | CAD, DCTD, DKC1, POLQ, POLR3E, POLR3K, RFC5, RRM1, TYMS, UCK2 | |
| AP | G2/M DNA damage checkpoint regulation | down | 2.04*E-4 | 6 | CCNB1, CCNB2, CDC25B, CHEK2, UBC, YWHAE | |
| LP | Purine metabolism | up | 9.20*E-3 | 12 | DDX39, PNPT1, POLA2, POLE2, POLR1B, POLR1C, POLR2I, RFC3, RRM2, RRM2B, RUVBL1, RUVBL2 | |
| LP | Pyrimidine metabolism | up | 6.15*E-7 | 14 | CTPS, PNPT1, POLA2, POLE2, POLR1B, POLR1C, POLR2I, PUS1, RFC3, RRM2, RRM2B, TXNRD1, TYMS, UCK2 | |
| LP | Mitotic roles of Polo- like kinase | up | 7.55*E-5 | 7 | ANAPC4, CDC27, CDK1, ESPL1, FZR1, PPP2R1B, PTTG1 | |
| LP | G2/M DNA damage checkpoint regulation | up | 3.09*E-2 | 3 | CDK1, CHEK1, YWHAZ | |
| LP | Wnt signaling | down | 4.02*E-2 | 9 | AKT3, FZD5, MMP7, NLK, SOX4, TCF3, TCF4, TCF7L2, WNT5A | |
| 1 dpn vs. 28 dpn | AP | AMPK signaling | up | 4.26*E-3 | 8 | AK1, CPT1A, EIF4EBP1, HMGCR, MAPK14, NOS3, PRKAA2, PRKAB2 |
| AP | mTOR signaling | up | 1.89*E-2 | 7 | EIF3F, EIF3G, EIF4EBP1, FNBP1, GNB1L, PRKAA2, PRKAB2 | |
| AP | Val, Leu, Ile degradation | down | 6.40*E-3 | 6 | ACAD8, ACADL, ACADSB, BCAT1, DBT, MCCC2 | |
| LP | Val, Leu, Ile degradation | up | 7.12*E-8 | 11 | ACADSB, ACAT1, ACAT2, ALDH1A1, AUH, BCKDHB, GCDH, HMGCL, HMGCS1, MCCC2, MCEE | |
| LP | Fatty acid metabolism | up | 3.23*E-3 | 8 | ACADSB, ACAT1, ACAT2, ALDH1A1, AUH, CYP51A1, GCDH, PECI | |
| LP | Synthesis and degradation of ketone bodies | up | 1.76*E-6 | 5 | ACAT1, ACAT2, BDH2, HMGCL, HMGCS1 | |
| LP | Biosynthesis of steroids | up | 3.27*E-4 | 5 | CYP24A1, FDPS, HMGCR, IDI1, SC5DL | |
| LP | Glucocorticoid receptor signaling | up | 3.57*E-3 | 12 | CDKN1C, CXCL3, IL10, MAP3K1, NCOA2, NFKBIB, NR3C1, POLR2B, PRKACB, RRAS2, SLPI, SMARCA4 | |
| LP | G1/S checkpoint regulation | down | 2.22*E-2 | 4 | CCNE1, CDC25A, CDKN1A, E2F3 | |
| 28 dpn vs. 188 dpn | AP | AMPK signaling | up | 1.50*E-3 | 10 | INSR, MAPK12, PPAT, PPM1A, PPP2CA, PPP2R3A, PRKAA2, SMARCA2, SRC, STK11 |
| AP | Fatty acid metabolism | up | 1.28*E-2 | 8 | ACADSB, ALDH1A1, CYP1B1, CYP2D6, CYP3A4, CYP4A11, CYP4B1, PECI | |
| AP | Mitotic roles of Polo- like kinase | down | 8.33*E-3 | 7 | ANAPC5, CDK1, PLK1, PLK2, PPP2R1B, SLK, WEE1 | |
| AP | VEGF signaling | down | 7.3*E-3 | 9 | AKT3, BCL2, KDR, NOS3, PRKCB, RAC2, RRAS, VCL, VEGFC | |
| LP | Val, Leu, Ile degradation | up | 1.07*E-2 | 7 | ACAA1, ACAT1, ALDH1B1, AUH, ECH1, IVD, IWS1 | |
| LP | Fatty acid elongation in mitochondria | up | 2.05*E-2 | 3 | ACAA1, AUH, ECH1 | |
| LP | mTOR signaling | up | 2.65*E-2 | 10 | AKT3, DDIT4, EIF4B, EIF4G3, PPP2R1B, PRKAB2, PRKAG1, PRKAG2, TSC1, VEGFA | |
| LP | Actin cytoskeleton signaling | down | 7.99*E-5 | 24 | ACTB, ACTR2, ARPC4, ARPC1A, CD14, CFL1, F2R, FGD1, LBP, MAP2K1, | |
| MYH9, NCKAP1, PAK2, PIK3C3, PIK3C2A, PIK3R4, PIKFYVE, PPP1R12A, RDX, ROCK1, ROCK2, TMSB4X, TMSL3, WASF1 | ||||||
| LP | RhoA signaling | dow | 5.05*E-3n | 12 | ACTB, ACTR2, ARHGAP1, ARPC4, ARPC1A, CFL1, PIKFYVE, PPP1R12A, RDX, ROCK1, ROCK2, WASF1 | |
| LP | Rac signaling | down | 4.34*E-3 | 12 | ACTR2, ARPC4, ARPC1A, CFL1, MAP2K1, NCKAP1, PAK2, PIK3C3, PIK3C2A, PIK3R4, PIKFYVE, WASF1 | |
| LP | Complement system | down | 2.17*E-2 | 5 | C2, C7, C9, CFB, MBL2 |
The comparison between the dietary gestational protein diets (LP vs. AP) is shown in dependence of the regulatory direction (up or down).